| Medical and Health Sciences | 2021-2025 | 623 | DE 42 | 99.87 |
| Rheumatology | Lifetime | 21 | DE 5 | 99.89 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 564 | DE 35 | 98.54 |
| Immunology | Lifetime | 523 | DE 39 | 98.50 |
| Hematology | Lifetime | 309 | DE 29 | 98.17 |
| Medical Genetics | Lifetime | 276 | DE 33 | 97.68 |
| Rheumatology | 2021-2025 | 11 | DE 4 | 99.73 |
| Immunology | 2021-2025 | 239 | DE 18 | 94.38 |
| Hematology | 2021-2025 | 172 | DE 25 | 94.79 |
| Medical Genetics | 2021-2025 | 181 | DE 29 | 92.19 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 13 | DE 4 | 99.90 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 12 | DE 3 | 99.83 |
| Systemic Lupus Erythematosus Research | Lifetime | 24 | DE 2 | 99.80 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 100 | DE 4 | 99.75 |
| Biosimilars and Bioanalytical Methods | Lifetime | 14 | DE 2 | 99.53 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 84 | DE 7 | 99.69 |
| Spondyloarthritis Studies and Treatments | Lifetime | 90 | DE 9 | 98.92 |
| Lymphoma Diagnosis and Treatment | Lifetime | 588 | DE 56 | 98.53 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 891 | DE 54 | 96.69 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 412 | DE 45 | 96.86 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 890 | DE 69 | 95.86 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 711 | DE 66 | 94.78 |
| Musculoskeletal Disorders and Rehabilitation | Lifetime | 771 | DE 92 | 84.51 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 682 | DE 40 | 84.32 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 6 | DE 2 | 99.77 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 11 | DE 4 | 99.55 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 14 | DE 1 | 98.80 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 105 | DE 8 | 98.65 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 125 | DE 6 | 97.85 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 76 | DE 12 | 97.51 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 450 | DE 32 | 90.24 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 257 | DE 20 | 83.31 |
| Pharmaceutical studies and practices | 2021-2025 | 418 | DE 35 | 84.03 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 758 | DE 40 | 83.42 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 737 | DE 77 | 83.25 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 186 | DE 4 | 74.81 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 683 | DE 37 | 74.53 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 339 | DE 19 | 73.06 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 966 | DE 40 | 69.48 |
| Intramuscular injections and effects | 2021-2025 | 318 | DE 19 | 42.47 |